Liver disease and chronic kidney disease patients are at higher risk of severe COVID-19 and death (search done on 14 April 2020)
Citation: Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Tropical Medicine and Infectious Disease. 2020 May 15;5(2):80.
What is this? COVID-19 patients with co-morbidities, such as liver and kidney disease, might be at higher risk of worse outcomes.
In this rapid review, the authors searched for studies reporting clinical characteristics and outcomes of COVID-19 patients with underlying kidney or liver disease. They restricted their searches to studies published in English between 21 November 2019 and 14 April 2020. They included 22 studies (total: 5595 COVID-19 patients), from China (21) and Italy (1), which they assessed to be at a low risk of bias.
What was found: At the time of this review, the included studies found that the prevalence of liver diseases and chronic kidney diseases in patients diagnosed with COVID-19 were 3% and 1%, respectively.
At the time of this review, the included studies found that the proportion of COVID-19 patients who had severe disease was 57% for those with liver disease and 84% for those with chronic kidney disease.
At the time of this review, the included studies found that the mortality rates for COVID-19 patients were 18% for those with liver disease and 53% for those with chronic kidney disease.